Publications by authors named "Dennis D Arnold"
Article Synopsis
- The study aimed to examine the effectiveness and safety of non-biological and biological disease-modifying anti-rheumatic drugs (nb/bDMARDs) for treating cardiac sarcoidosis (CS), focusing on myocardial inflammation measured by F-FDG PET/CT.!
- A retrospective analysis of 50 CS patients showed that while most were treated with prednisone and nb/bDMARDs, only adalimumab significantly reduced cardiac metabolic activity on follow-up scans compared to other treatments.!
- TNF inhibitors (TNFi) not only provided better control over myocardial inflammation but were also safe and improved heart function in patients with severely reduced left ventricular ejection fraction (LVEF).!*
Background: The cytokine interleukin (IL)-1 plays a pivotal role in immune-mediated disorders, particularly in autoinflammatory diseases. Targeting this cytokine proved to be efficacious in treating numerous IL-1-mediated pathologies. Currently, three IL-1 blockers are approved, namely anakinra, canakinumab and rilonacept, and two additional ones are expected to receive approval, namely gevokizumab and bermekimab.
View Article and Find Full Text PDF